Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220954) titled 'A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234' on Oct. 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AstraZeneca
Condition:
Healthy Participants
Intervention:
Drug: AZD6234 Formulation 1
Drug: AZD6234 Formulation 2 (low concentration)
Drug: AZD6234 Formulation 2 (high concentration)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 10, 2025
Target Sample Size: 21
Countries of Recruitm...